	US 11,739,143 B2
	Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same
Hiroshi Eguchi, Tokyo (JP); Takashi Murakami, Tokyo (JP); Naoko Namiki, Tokyo (JP); Akira Tanokura, Tokyo (JP); Jeanne E. Baker, Redwood City, CA (US); Sophie Parmentier Batteur, Haverford, PA (US); Angela Marie Jablonski, North Wales, PA (US); Daniel Stephen Malashock, San Jose, CA (US); Carl Mieczkowski, Mountain View, CA (US); and Gopalan (Raghu) Raghunathan, Santa Clara, CA (US)
Assigned to TEIJIN PHARMA LIMITED, Tokyo (JP); and MERCK SHARP & DOHME LLC, Rahway, NJ (US)
Filed by TEIJIN PHARMA LIMITED, Tokyo (JP); and MERCK SHARP & DOHME CORP., Rahway, NJ (US)
Filed on Dec. 15, 2020, as Appl. No. 17/122,325.
Application 17/122,325 is a continuation of application No. 16/746,725, filed on Jan. 17, 2020, granted, now 10,894,829.
Application 16/746,725 is a continuation of application No. 15/906,773, filed on Feb. 27, 2018, granted, now 10,556,950, issued on Feb. 11, 2020.
Claims priority of application No. 2017-035594 (JP), filed on Feb. 27, 2017.
Prior Publication US 2021/0380677 A1, Dec. 9, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); C07K 16/18 (2006.01); A61P 25/16 (2006.01); A61P 25/28 (2006.01); C07K 16/06 (2006.01); C07K 16/40 (2006.01); C07K 16/44 (2006.01)

CPC C07K 16/28 (2013.01) [A61P 25/16 (2018.01); A61P 25/28 (2018.01); C07K 16/065 (2013.01); C07K 16/18 (2013.01); C07K 16/40 (2013.01); C07K 16/44 (2013.01); C07K 2317/24 (2013.01); C07K 2317/56 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)]

16 Claims

1. An anti-pSer413 tau antibody or antigen binding fragment thereof comprising:

(A) a vhCDR1, a vhCDR2, and a vhCDR3 as set forth in the VH domain having an amino acid sequence of SEQ ID NO:116; and

(B) a vlCDR1, a vlCDR2, and a vlCDR3 as set forth in the VL domain having an amino acid sequence selected from the group consisting of:

i. SEQ ID NO:103;

ii. SEQ ID NO:104;

iii. SEQ ID NO:105;

iv. SEQ ID NO:106;

v. SEQ ID NO:107;

vi. SEQ ID NO:108;

vii. SEQ ID NO:109;

viii. SEQ ID NO:110;

ix. SEQ ID NO:111;

x. SEQ ID NO:112;

xi. SEQ ID NO:113; and

xii. SEQ ID NO:114.